Kimball Electronics, Inc. · NASDAQ:KE
Kimball Electronics — Merger or Acquisition (July 2026)
20 slides from Kimball Electronics's merger presentation, Jul 1, 2026
Slide 1: Strategic Update: Acquisition of Helvoet Polymer Technologies B.V.
Strategic Update Acquisition of Helvoet Polymer Technologies B.V. July 1, 2026 Lasting relationships. Global success. Kimball Electronics Confidential
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements contained within this supplementary information and any statements made during our strategic update may be considered forward-looking under the Private Securities Litigation Reform Act of 1995. The statements may be identified by the use of words such as “exp
Slide 3: Today's Speakers and Agenda
Today’s Speakers Agenda • Opening comments on the strategic fit of the acquisition • Financial profile of Helvoet • Terms of the transaction • Closing comments Ric Phillips Jana Croom CEO CFO • Q&A Lasting relationships. Global success. 3 Kimball Electronics Confidential
Slide 4: Acquiring Helvoet Polymer Technologies B.V.
Acquiring Helvoet Polymer Technologies B.V. • Helvoet Polymer Technologies B.V. • Contract Development and Manufacturing Organization (CDMO) based in Europe and India • Focus on microfluidics, diagnostics, and drug delivery applications • Transaction valued at a purchase price of €90 million, or ~$1
Slide 5: Another meaningful step in our journey to expand our CMO capabilities
Another meaningful step in our journey to expand our CMO capabilities • Strategically position the Company with an increased presence and penetration in the medical industry • Decisions: • Divested non-core assets • Strengthened balance sheet • Streamlined manufacturing network • Opened facility in
Slide 6: Expand medical manufacturing capabilities with M&A
Expand medical manufacturing capabilities with M&A • Deepen relationships with leading healthcare customers • Build a broader global footprint capable of supporting medical companies across the full product lifecycle • Helvoet is a good start toward reaching those objectives • Brings additional capa
Slide 7: Based in the Netherlands, Helvoet was founded in 1939
Based in the Netherlands, Helvoet was founded in 1939 • Operating most recently as a wholly-owned subsidiary of Hydratec Industries • Manufacturing facilities in Tilburg, Netherlands, and Pune, India • Approximately 70% of revenue supports medical end markets • Remainder is derived outside of medica
Slide 8: Helvoet has established itself as a world class provider
Under the leadership of CEO Eveline Hogenkamp, Helvoet has established itself as a world class provider • Advanced medical manufacturing solutions that include highly automated micro molding and precision injection technologies that serve: • Microfluidics • Diagnostics • Drug delivery • Three areas
Slide 9: For example…
For example… • In microfluidics, product dimensions are measured in microns where even minor variations can impact fluid flow, test accuracy, and overall device performance • Products require: • Specialized tooling • Advanced process controls • Highly automated manufacturing environments • Deep mate
Slide 10: Also true across drug delivery applications
Also true across drug delivery applications • Reliability, consistency, and regulatory compliance are critical given the direct impact these devices can have on patient outcomes • Customers prioritize proven engineering expertise, quality systems, and long-term manufacturing partners over simply sel
Slide 11: Helvoet has built long-standing relationships…
Helvoet has built long-standing relationships… • Blue-chip customer base is highly complementary to our existing portfolio • Meaningful opportunities to expand customer engagements • Pursue larger and more complex programs • Leverage the combined capabilities of the platform to support customers thr
Slide 12: Geographic footprint offers future growth potential…
Geographic footprint offers future growth potential… • Strengthened presence in Europe • Immediate access to the rapidly growing medical market in India • Clear pathway to accelerate growth through our facility in Indianapolis by providing Helvoet a much-needed manufacturing location in the United S
Slide 13: Helvoet financials in calendar 2025
Helvoet financials in calendar 2025 • Revenue of approximately $56 million • EBITDA margin rate in the mid-teens • Geographically, nearly 60% of revenue was shipped to customers in Europe, and almost 40% to Asia • Demonstrates the global nature of the customer base and the opportunity for future exp
Slide 14: From a Medical end market perspective…
From a Medical end market perspective… • Over 50% of revenue is derived from in-vitro diagnostics: • Diagnostic and microfluidic applications such as point-of-care testing cartridges, blood warming cartridges, and blood filtration solutions • ~10% of revenue comes from drug delivery • Disposable syr
Slide 15: Customer concentration is manageable
Customer concentration is manageable • Top ten customers representing approximately 70% of total revenue • Helvoet has maintained an average relationship tenure over 10 years • Consistent with our focus on long-standing customer relationships Lasting relationships. Global success. 15 Kimball Electro
Slide 16: Based on our estimates for calendar 2026 and projections for future years
Based on our estimates for calendar 2026 and projections for future years • Transaction will be accretive to our fiscal 2027 adjusted earnings • Sales in the Kimball medical vertical increasing in the low double-digit range • Unique opportunity to acquire a highly attractive medical manufacturing as
Slide 17: Purchase price was €90 million, or ~$103 million
Purchase price was €90 million, or ~$103 million • Funded the acquisition through a combination of cash and available borrowing capacity on our existing lines of credit • Pro forma leverage profile remains consistent with the capital allocation priorities of the Company Transaction is strategically
Slide 18: Helvoet has the characteristics we look for in an acquisition
Helvoet has the characteristics we look for in an acquisition • Differentiated medical CDMO platform with expertise in materials science, precision manufacturing, automation, and customer development • An accretive expansion opportunity that deepens our presence in Europe, provides access to the eme
Slide 19: Excited to welcome Helvoet to the Kimball family
Excited to welcome Helvoet to the Kimball family • Brings together two organizations that share a commitment to engineering excellence, operational quality, customer partnership, and long-term value creation • Over time, we will rebrand the Tilburg and Pune facilities as Kimball Solutions… but this
Slide 20: For more information, please contact:
For more information, please contact: Andy Regrut Vice President, Investor Relations, Strategic Development, and Treasurer 812–827–4151 andy.regrut@kimballelectronics.com Lasting relationships. Global success. 20 Kimball Electronics Confidential
Kimball Electronics — Merger or Acquisition (July 2026) on 6ix